Compass Therapeutics, Inc. (CMPX) - Q2 2024 Filing Summary
Business Context and Reporting Period
This summary covers the Quarterly Report on Form 10-Q for Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company. The reporting period ended June 30, 2024. The company develops proprietary antibody-based therapeutics targeting angiogenesis and the immune system, with a pipeline including CTX-009, CTX-471, and CTX-8371.
Key Financial Metrics
| Metric | Q2 2024 (3 Months) | YTD 2024 (6 Months) | YTD 2023 (6 Months) |
|---|---|---|---|
| Licensing Revenue | $0.85 million | $0.85 million | $0 |
| Net Loss | $(13.1) million | $(23.9) million | $(19.1) million |
| Net Loss Per Share | $(0.10) | $(0.17) | $(0.15) |
| Operating Expenses | $15.9 million | $28.7 million | $23.0 million |
| Cash & Marketable Securities | $146.2 million (as of June 30, 2024) | ||
| Cash Used in Operations (YTD) | $24.6 million |
Material Changes vs. Prior Period
- Revenue: The company recognized $0.85 million in licensing revenue in Q2 2024, compared to zero in the prior year period. This resulted from a $1.0 million milestone payment from Elpiscience for completing a Phase 1 trial of CTX-009 in China, reported net of a 15% sublicense royalty.
- Operating Expenses: Total operating expenses increased by $2.6 million (19%) in Q2 and $5.6 million (24%) YTD compared to 2023.
- R&D: Increased primarily due to higher clinical costs for the COMPANION-002 trial (CTX-009), partially offset by reduced manufacturing expenses.
- G&A: Increased significantly (52% in Q2, 29% YTD) largely due to accruals associated with the CEO transition.
- Capital Raise: In Q1 2024, the company sold approximately 9.8 million shares via its ATM agreement, raising net proceeds of $17.6 million. No ATM sales occurred in Q2 2024.
Outlook, Guidance, and Risks
- Liquidity: Management expects current cash resources ($146.2 million) to fund operations into the first quarter of 2027. No specific financial guidance was provided beyond this runway estimate.
- Clinical Updates:
- CTX-009: The Phase 2 monotherapy trial in colorectal cancer did not meet criteria to advance to the second stage (5% ORR). The company will not enroll the second stage but is evaluating a second-line combination trial. The Phase 2/3 trial in biliary tract cancer (BTC) is fully enrolled, with data expected in Q1 2025. The FDA granted Fast Track Designation for CTX-009 in BTC.
- CTX-471: A combination study with Merck's KEYTRUDA was discontinued due to unexpected cytokine suppression. A Phase 2 monotherapy study is being planned.
- CTX-8371: First patient dosed in April 2024; first cohort completed in June 2024 with no dose-limiting toxicities.
- Risks: The company remains dependent on equity financing. Failure to raise additional capital could force delays or termination of development programs. Clinical trial outcomes remain uncertain.
Investor Verification Checklist
- Runway Validation: Confirm the $146 million cash balance and the assumption that it funds operations through Q1 2027 given the increased burn rate.
- CTX-009 Strategy: Verify the rationale and timeline for the new second-line combination trial in colorectal cancer following the monotherapy trial's failure to advance.
- CEO Transition Costs: Review the specific impact of the CEO transition on future G&A expenses and whether these are one-time or recurring.
- CTX-471 Pivot: Assess the timeline and design of the new Phase 2 monotherapy study for CTX-471 following the discontinuation of the Merck collaboration.
- ATM Availability: Check the remaining capacity under the At-The-Market (ATM) agreement with Jefferies LLC for future capital raises.